BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 14, 2006
View Archived Issues
Greenwood Planning More Time Spent On Capitol Hill
Read More
Affymax Partners Anemia Drug In Japan For $102M
Less than a month after Affymax Inc. started the fourth Phase II trial of its lead product, Hematide, to treat anemia, the company signed a partnership deal in Japan worth up to $102 million. (BioWorld Today)
Read More
Replidyne Gets $50M Up Front Through Forest Collaboration
Read More
Novacea’s IPO Seeks $75M To Fund Late-Stage DN-101
Read More
Avastin Study Suspended Because Of Patient Deaths
Read More
Caliper Buying Xenogen: $80M In Stock, Warrants
Read More
Other News To Note
Read More
Clinic Roundup
Read More